Hannah Goulart

13PUBLICATIONS
44CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursMedical infection agents (incl. prions)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jun 27, 2026
Inotuzumab ozogamicin therapy for measurable residual disease in adult acute lymphoblastic leukemia.

|Apr 26, 2026
Hyper-CVAD Versus Hyper-CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity-Score Analysis.

|Apr 24, 2026
Blinatumomab and Ponatinib Versus Hyper-CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis.

|Mar 20, 2026
Mutations in isocitrate dehydrogenase portend a poor prognosis in adult patients with acute lymphoblastic leukemia.

Hannah Goulart, Nicholas J Short, Gautam Borthakur

|Dec 10, 2025
Clinical Outcomes of Adult Patients With Newly Diagnosed Mixed Phenotype Acute Leukemia.

Hannah Goulart, Farhad Ravandi, Nicholas J Short

|Aug 27, 2025
Contemporary Outcomes of Adults With Acute Lymphoblastic Leukemia With KMT2A Rearrangements Treated With Immunotherapy-Based Regimens.

Hannah Goulart, Elias Jabbour, Nicholas Short

Pageof 3

Frequent Collaborators

8 joint publications

Tapan M Kadia

7 joint publications

Farhad Ravandi

6 joint publications

Caitlin Rausch

6 joint publications

Courtney DiNardo